Abstract
Immune checkpoint inhibitors (ICIs) represent a new standard of care for patients with advanced nonsmall cell lung cancer, improving overall survival compared with standard chemotherapy. However, a new pattern of response to ICIs characterized by accelerated tumor growth has been recently described, termed hyperprogressive disease (HPD). We report the case of a 73-year-old patient with advanced lung adenocarcinoma who developed HPD following treatment with a unique dose of atezolizumab for a skin metastasis that was refractory to chemotherapy and radiotherapy. Potential clinical biomarkers related to HPD to ICIs are reviewed.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma of Lung / drug therapy*
-
Adenocarcinoma of Lung / pathology
-
Aged
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antineoplastic Agents, Immunological / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Humans
-
Immunotherapy / adverse effects*
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / pathology
-
Male
-
Shoulder / pathology
-
Skin Neoplasms / drug therapy
-
Skin Neoplasms / radiotherapy*
-
Skin Neoplasms / secondary
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
atezolizumab